{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T08:26:56Z","timestamp":1776068816849,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Major Medical Science and Technology Projects in Henan Province","award":["SBGJ202001006"],"award-info":[{"award-number":["SBGJ202001006"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s00228-025-03803-z","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T08:02:40Z","timestamp":1737532960000},"page":"479-493","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Grade\u2009\u2265\u20093 hematologic adverse events of immunotherapy in advanced NSCLC patients: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"81","author":[{"given":"Shuang","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengting","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yajun","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianyi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoya","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuying","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunhua","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiguo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"issue":"8","key":"3803_CR1","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1002\/cncr.35128","volume":"130","author":"TB Kratzer","year":"2024","unstructured":"Kratzer TB, Bandi P, Freedman ND, Smith RA, Travis WD, Jemal A, Siegel RL (2024) Lung cancer statistics, 2023. Cancer 130(8):1330\u20131348","journal-title":"Cancer"},{"issue":"1","key":"3803_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17\u201348","journal-title":"CA Cancer J Clin"},{"key":"3803_CR3","doi-asserted-by":"publisher","first-page":"102545","DOI":"10.1016\/j.ctrv.2023.102545","volume":"116","author":"A Desai","year":"2023","unstructured":"Desai A, Peters S (2023) Immunotherapy-based combinations in metastatic NSCLC. Cancer Treat Rev 116:102545","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"3803_CR4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","volume":"22","author":"A Lahiri","year":"2023","unstructured":"Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, Mukherjee A, Paul MK (2023) Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer 22(1):40","journal-title":"Mol Cancer"},{"issue":"6","key":"3803_CR5","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/JCO.21.01497","volume":"40","author":"M Reck","year":"2022","unstructured":"Reck M, Remon J, Hellmann MD (2022) First-line immunotherapy for non-small-cell lung cancer. J Clin Oncol 40(6):586\u2013597","journal-title":"J Clin Oncol"},{"issue":"2","key":"3803_CR6","doi-asserted-by":"publisher","first-page":"ITC17","DOI":"10.7326\/AITC202402200","volume":"177","author":"M Ramos-Casals","year":"2024","unstructured":"Ramos-Casals M, Siso-Almirall A (2024) Immune-related adverse events of immune checkpoint inhibitors. Ann Intern Med 177(2):ITC17\u2013ITC12","journal-title":"Ann Intern Med"},{"issue":"25","key":"3803_CR7","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1182\/blood.2020009016","volume":"139","author":"MH Kroll","year":"2022","unstructured":"Kroll MH, Rojas-Hernandez C, Yee C (2022) Hematologic complications of immune checkpoint inhibitors. Blood 139(25):3594\u20133604","journal-title":"Blood"},{"issue":"5","key":"3803_CR8","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1634\/theoncologist.2018-0574","volume":"24","author":"EJ Davis","year":"2019","unstructured":"Davis EJ, Salem JE, Young A, Green JR, Ferrell PB, Ancell KK, Lebrun-Vignes B, Moslehi JJ, Johnson DB (2019) Hematologic complications of immune checkpoint inhibitors. Oncologist 24(5):584\u2013588","journal-title":"Oncologist"},{"key":"3803_CR9","doi-asserted-by":"publisher","first-page":"e941789","DOI":"10.12659\/AJCR.941789","volume":"24","author":"L Rueda Prada","year":"2023","unstructured":"Rueda Prada L, Gavrancic T, Cadena Sanabria MO, Dumic I, Bourgeois K, King RL, Yan Y (2023) Immune checkpoint inhibitor-induced pure red cell aplasia: a review of 2 cases in metastatic melanoma. Am J Case Rep 24:e941789","journal-title":"Am J Case Rep"},{"issue":"7","key":"3803_CR10","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","volume":"5","author":"Y Wang","year":"2019","unstructured":"Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, Shen C, Duma N, Vera Aguilera J, Chintakuntlawar A, Price KA, Molina JR, Pagliaro LC, Halfdanarson TR, Grothey A, Markovic SN, Nowakowski GS, Ansell SM, Wang ML (2019) Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol 5(7):1008\u20131019","journal-title":"JAMA Oncol"},{"issue":"1","key":"3803_CR11","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","volume":"6","author":"N Delanoy","year":"2019","unstructured":"Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J, Dupont R, Champiat S, Chahine C, Robert C, Herbaux C, Besse B, Guillemin A, Mateus C, Pautier P, Saiag P, Madonna E, Maerevoet M, Bout JC, Leduc C, Biscay P, Quere G, Nardin C, Ebbo M, Albiges L, Marret G, Levrat V, Dujon C, Vargaftig J, Laghouati S, Croisille L, Voisin AL, Godeau B, Massard C, Ribrag V, Marabelle A, Michel M, Lambotte O (2019) Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol 6(1):e48\u2013e57","journal-title":"Lancet Haematol"},{"key":"3803_CR12","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ejca.2021.01.013","volume":"147","author":"R Kramer","year":"2021","unstructured":"Kramer R, Zaremba A, Moreira A, Ugurel S, Johnson DB, Hassel JC, Salzmann M, Gesierich A, Weppler A, Spain L, Loquai C, Dudda M, Pfohler C, Hepner A, Long GV, Menzies AM, Carlino MS, Sachse MM, Lebbe C, Baroudjian B, Enokida T, Tahara M, Schlaak M, Hayani K, Brockelmann PJ, Meier F, Reinhardt L, Friedlander P, Eigentler T, Kahler KC, Berking C, Zimmer L, Heinzerling L (2021) Hematological immune related adverse events after treatment with immune checkpoint inhibitors. Eur J Cancer 147:170\u2013181","journal-title":"Eur J Cancer"},{"key":"3803_CR13","doi-asserted-by":"crossref","unstructured":"Johnson ML, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Laktionov K, Kim SW, Ursol G, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Shi X, Poole L, Peters S, Garon EB, Mok T, investigators P (2023) Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study. J Clin Oncol 41(6):1213\u20131227","DOI":"10.1200\/JCO.22.00975"},{"issue":"5","key":"3803_CR14","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/jamaoncol.2021.0366","volume":"7","author":"J Wang","year":"2021","unstructured":"Wang J, Lu S, Yu X, Hu Y, Sun Y, Wang Z, Zhao J, Yu Y, Hu C, Yang K, Feng G, Ying K, Zhuang W, Zhou J, Wu J, Leaw SJ, Zhang J, Lin X, Liang L, Yang N (2021) Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial. JAMA Oncol 7(5):709\u2013717","journal-title":"JAMA Oncol"},{"issue":"2","key":"3803_CR15","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/S1470-2045(21)00650-1","volume":"23","author":"C Zhou","year":"2022","unstructured":"Zhou C, Wang Z, Sun Y, Cao L, Ma Z, Wu R, Yu Y, Yao W, Chang J, Chen J, Zhuang W, Cui J, Chen X, Lu Y, Shen H, Wang J, Li P, Qin M, Lu D, Yang J (2022) Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. Lancet Oncol 23(2):220\u2013233","journal-title":"Lancet Oncol"},{"key":"3803_CR16","doi-asserted-by":"crossref","unstructured":"de Castro G Jr, Kudaba I, Wu YL, Lopes G, Kowalski DM, Turna HZ, Caglevic C, Zhang L, Karaszewska B, Laktionov KK, Srimuninnimit V, Bondarenko I, Kubota K, Mukherjee R, Lin J, Souza F, Mok TSK, Cho BC (2023) Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score >\/= 1% in the KEYNOTE-042 study. J Clin Oncol 41(11):1986-1991.","DOI":"10.1200\/JCO.21.02885"},{"issue":"21","key":"3803_CR17","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.21.00174","volume":"39","author":"M Reck","year":"2021","unstructured":"Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O\u2019Brien M, Rao S, Hotta K, Leal TA, Riess JW, Jensen E, Zhao B, Pietanza MC, Brahmer JR (2021) Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score >\/= 50. J Clin Oncol 39(21):2339\u20132349","journal-title":"J Clin Oncol"},{"issue":"2","key":"3803_CR18","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","volume":"22","author":"L Paz-Ares","year":"2021","unstructured":"Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Salman P, Souquet PJ, De Marchi P, Martin C, Perol M, Scherpereel A, Lu S, John T, Carbone DP, Meadows-Shropshire S, Agrawal S, Oukessou A, Yan J, Reck M (2021) First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol 22(2):198\u2013211","journal-title":"Lancet Oncol"},{"issue":"6","key":"3803_CR19","doi-asserted-by":"publisher","first-page":"102065","DOI":"10.1016\/j.esmoop.2023.102065","volume":"8","author":"H Borghaei","year":"2023","unstructured":"Borghaei H, O\u2019Byrne KJ, Paz-Ares L, Ciuleanu TE, Yu X, Pluzanski A, Nagrial A, Havel L, Kowalyszyn RD, Valette CA, Brahmer JR, Reck M, Ramalingam SS, Zhang L, Ntambwe I, Rabindran SK, Nathan FE, Balli D, Wu YL (2023) Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial. ESMO Open 8(6):102065","journal-title":"ESMO Open"},{"issue":"2","key":"3803_CR20","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jtho.2021.09.010","volume":"17","author":"LG Paz-Ares","year":"2022","unstructured":"Paz-Ares LG, Ramalingam SS, Ciuleanu TE, Lee JS, Urban L, Caro RB, Park K, Sakai H, Ohe Y, Nishio M, Audigier-Valette C, Burgers JA, Pluzanski A, Sangha R, Gallardo C, Takeda M, Linardou H, Lupinacci L, Lee KH, Caserta C, Provencio M, Carcereny E, Otterson GA, Schenker M, Zurawski B, Alexandru A, Vergnenegre A, Raimbourg J, Feeney K, Kim SW, Borghaei H, O\u2019Byrne KJ, Hellmann MD, Memaj A, Nathan FE, Bushong J, Tran P, Brahmer JR, Reck M (2022) First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial. J Thorac Oncol 17(2):289\u2013308","journal-title":"J Thorac Oncol"},{"key":"3803_CR21","doi-asserted-by":"crossref","unstructured":"de Castro G Jr, Rizvi NA, Schmid P, Syrigos K, Martin C, Yamamoto N, Cheng Y, Moiseyenko V, Summers Y, Vynnychenko I, Lee SY, Bryl M, Zer A, Erman M, Timcheva C, Raja R, Naicker K, Scheuring U, Walker J, Mann H, Chand V, Mok T, Investigators N (2023) NEPTUNE: phase 3 study of first-line durvalumab plus tremelimumab in patients with metastatic NSCLC. J Thorac Oncol 18(1):106-119","DOI":"10.1016\/j.jtho.2022.09.223"},{"issue":"30","key":"3803_CR22","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1200\/JCO.2016.71.7629","volume":"35","author":"R Govindan","year":"2017","unstructured":"Govindan R, Szczesna A, Ahn MJ, Schneider CP, Gonzalez Mella PF, Barlesi F, Han B, Ganea DE, Von Pawel J, Vladimirov V, Fadeeva N, Lee KH, Kurata T, Zhang L, Tamura T, Postmus PE, Jassem J, O\u2019Byrne K, Kopit J, Li M, Tschaika M, Reck M (2017) Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer. J Clin Oncol 35(30):3449\u20133457","journal-title":"J Clin Oncol"},{"issue":"11","key":"3803_CR23","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1038\/s41591-022-01977-y","volume":"28","author":"M Gogishvili","year":"2022","unstructured":"Gogishvili M, Melkadze T, Makharadze T, Giorgadze D, Dvorkin M, Penkov K, Laktionov K, Nemsadze G, Nechaeva M, Rozhkova I, Kalinka E, Gessner C, Moreno-Jaime B, Passalacqua R, Li S, McGuire K, Kaul M, Paccaly A, Quek RGW, Gao B, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Gullo G, Rietschel P (2022) Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. Nat Med 28(11):2374\u20132380","journal-title":"Nat Med"},{"issue":"5","key":"3803_CR24","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jtho.2022.12.017","volume":"18","author":"C Zhou","year":"2023","unstructured":"Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, Wang Z, Shu Y, Shi J, Hu Y, Wang Q, Cheng Y, Wu F, Chen J, Lin X, Wang Y, Huang J, Cui J, Cao L, Liu Y, Zhang Y, Pan Y, Zhao J, Wang L, Chang J, Chen Q, Ren X, Zhang W, Fan Y, He Z, Fang J, Gu K, Dong X, Jin F, Gao H, An G, Ding C, Jiang X, Xiong J, Zhou X, Hu S, Lu P, Liu A, Guo S, Huang J, Zhu C, Zhao J, Gao B, Chen Y, Hu C, Zhang J, Zhang H, Zhao H, Tai Y, Ma X, Shi W, Came LSG (2023) Camrelizumab plus carboplatin and pemetrexed as first-line treatment for advanced nonsquamous NSCLC: extended follow-up of CameL Phase 3 trial. J Thorac Oncol 18(5):628\u2013639","journal-title":"J Thorac Oncol"},{"issue":"7","key":"3803_CR25","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp HG, Daniel D, McCune S, Mekhail T, Zer A, Reinmuth N, Sadiq A, Sandler A, Lin W, Ochi Lohmann T, Archer V, Wang L, Kowanetz M, Cappuzzo F (2019) Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20(7):924\u2013937","journal-title":"Lancet Oncol"},{"issue":"25","key":"3803_CR26","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","volume":"376","author":"DP Carbone","year":"2017","unstructured":"Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR Jr, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA, CheckMate I (2017) First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med 376(25):2415\u20132426","journal-title":"N Engl J Med"},{"issue":"5","key":"3803_CR27","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1001\/jamaoncol.2020.0237","volume":"6","author":"NA Rizvi","year":"2020","unstructured":"Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn MJ, van den Heuvel MM, Cobo M, Vicente D, Smolin A, Moiseyenko V, Antonia SJ, Le Moulec S, Robinet G, Natale R, Schneider J, Shepherd FA, Geater SL, Garon EB, Kim ES, Goldberg SB, Nakagawa K, Raja R, Higgs BW, Boothman AM, Zhao L, Scheuring U, Stockman PK, Chand VK, Peters S, Investigators M (2020) Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the MYSTIC phase 3 randomized clinical trial. JAMA Oncol 6(5):661\u2013674","journal-title":"JAMA Oncol"},{"issue":"1","key":"3803_CR28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jtho.2022.09.217","volume":"18","author":"C Zhou","year":"2023","unstructured":"Zhou C, Huang D, Fan Y, Yu X, Liu Y, Shu Y, Ma Z, Wang Z, Cheng Y, Wang J, Hu S, Liu Z, Poddubskaya E, Disel U, Akopov A, Dvorkin M, Zheng W, Ma Y, Wang Y, Li S, Yu C, Rivalland G (2023) Tislelizumab versus docetaxel in patients with previously treated advanced NSCLC (RATIONALE-303): a phase 3, open-label, randomized controlled trial. J Thorac Oncol 18(1):93\u2013105","journal-title":"J Thorac Oncol"},{"issue":"3","key":"3803_CR29","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/ijc.34532","volume":"153","author":"S Ren","year":"2023","unstructured":"Ren S, Feng J, Ma S, Chen H, Ma Z, Huang C, Zhang L, He J, Wang C, Zhou J, Danchaivijtr P, Wang CC, Vynnychenko I, Wang K, Orlandi F, Sriuranpong V, Li B, Ge J, Dang T, Zhou C (2023) KEYNOTE-033: randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC. Int J Cancer 153(3):623\u2013634","journal-title":"Int J Cancer"},{"issue":"10","key":"3803_CR30","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/j.jtho.2021.05.001","volume":"16","author":"RS Herbst","year":"2021","unstructured":"Herbst RS, Garon EB, Kim DW, Cho BC, Gervais R, Perez-Gracia JL, Han JY, Majem M, Forster MD, Monnet I, Novello S, Gubens MA, Boyer M, Su WC, Samkari A, Jensen EH, Kobie J, Piperdi B, Baas P (2021) Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC. J Thorac Oncol 16(10):1718\u20131732","journal-title":"J Thorac Oncol"},{"key":"3803_CR31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.lungcan.2021.12.009","volume":"165","author":"J Chang","year":"2022","unstructured":"Chang J, Wu YL, Lu S, Wang J, Mok T, Zhang L, Feng J, Wu L, Tu HY, Zhang Y, Luft A, Zhou JY, Ma Z, Lu Y, Hu C, Shi Y, Poddubskaya E, Soo RA, Chia YH, Penrod JR, Taylor F, Lawrance R, Blum SI, Sun X, Juarez-Garcia A, Moreno-Koehler A, Li A, Li A, Cheng Y (2022) Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer. Lung Cancer 165:71\u201381","journal-title":"Lung Cancer"},{"issue":"2","key":"3803_CR32","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Aren Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123\u2013135","journal-title":"N Engl J Med"},{"issue":"17","key":"3803_CR33","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crino L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627\u20131639","journal-title":"N Engl J Med"},{"issue":"8","key":"3803_CR34","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.jtho.2021.03.009","volume":"16","author":"K Park","year":"2021","unstructured":"Park K, Ozguroglu M, Vansteenkiste J, Spigel D, Yang JCH, Ishii H, Garassino M, de Marinis F, Szczesna A, Polychronis A, Uslu R, Krzakowski M, Lee JS, Calabro L, Aren Frontera O, Xiong H, Bajars M, Ruisi M, Barlesi F (2021) Avelumab versus docetaxel in patients with platinum-treated advanced NSCLC: 2-year follow-up from the JAVELIN Lung 200 phase 3 trial. J Thorac Oncol 16(8):1369\u20131378","journal-title":"J Thorac Oncol"},{"issue":"12","key":"3803_CR35","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/cac2.12385","volume":"42","author":"Y Shi","year":"2022","unstructured":"Shi Y, Wu L, Yu X, Xing P, Wang Y, Zhou J, Wang A, Shi J, Hu Y, Wang Z, An G, Fang Y, Sun S, Zhou C, Wang C, Ye F, Li X, Wang J, Wang M, Liu Y, Zhao Y, Yuan Y, Feng J, Chen Z, Shi J, Sun T, Wu G, Shu Y, Guo Q, Zhang Y, Song Y, Zhang S, Chen Y, Li W, Niu H, Hu W, Wang L, Huang J, Zhang Y, Cheng Y, Wu Z, Peng B, Sun J, Mancao C, Wang Y, Sun L (2022) Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3). Cancer Commun (Lond) 42(12):1314\u20131330","journal-title":"Cancer Commun (Lond)"},{"issue":"9","key":"3803_CR36","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/S1470-2045(23)00329-7","volume":"24","author":"M Ozguroglu","year":"2023","unstructured":"Ozguroglu M, Kilickap S, Sezer A, Gumus M, Bondarenko I, Gogishvili M, Nechaeva M, Schenker M, Cicin I, Ho GF, Kulyaba Y, Zyuhal K, Scheusan RI, Garassino MC, He X, Kaul M, Okoye E, Li Y, Li S, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P (2023) First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial. Lancet Oncol 24(9):989\u20131001","journal-title":"Lancet Oncol"},{"issue":"7","key":"3803_CR37","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1002\/2211-5463.13445","volume":"12","author":"K He","year":"2022","unstructured":"He K, Liu X, Hoffman RD, Shi RZ, Lv GY, Gao JL (2022) G-CSF\/GM-CSF-induced hematopoietic dysregulation in the progression of solid tumors. FEBS Open Bio 12(7):1268\u20131285","journal-title":"FEBS Open Bio"},{"issue":"8","key":"3803_CR38","doi-asserted-by":"publisher","first-page":"3606","DOI":"10.1007\/s12325-020-01419-6","volume":"37","author":"RS Epstein","year":"2020","unstructured":"Epstein RS, Aapro MS, Basu Roy UK, Salimi T, Krenitsky J, Leone-Perkins ML, Girman C, Schlusser C, Crawford J (2020) Patient burden and real-world management of chemotherapy-induced myelosuppression: results from an online survey of patients with solid tumors. Adv Ther 37(8):3606\u20133618","journal-title":"Adv Ther"},{"issue":"17","key":"3803_CR39","doi-asserted-by":"publisher","first-page":"5748","DOI":"10.1002\/cam4.4089","volume":"10","author":"R Ferrarotto","year":"2021","unstructured":"Ferrarotto R, Anderson I, Medgyasszay B, Garcia-Campelo MR, Edenfield W, Feinstein TM, Johnson JM, Kalmadi S, Lammers PE, Sanchez-Hernandez A, Pritchett Y, Morris SR, Malik RK, Csoszi T (2021) Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: pooled analysis of three randomized phase 2 trials. Cancer Med 10(17):5748\u20135756","journal-title":"Cancer Med"},{"issue":"4","key":"3803_CR40","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.3390\/cancers15041078","volume":"15","author":"M Li","year":"2023","unstructured":"Li M, Wang Q, Lu P, Zhang D, Hua Y, Liu F, Liu X, Lin T, Wei G, He D (2023) Development of a Machine Learning-Based Prediction Model for Chemotherapy-Induced Myelosuppression in Children with Wilms\u2019 Tumor. Cancers 15(4):1078","journal-title":"Cancers"},{"issue":"1","key":"3803_CR41","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1186\/s12885-023-11692-7","volume":"23","author":"Z Song","year":"2023","unstructured":"Song Z, Ma H, Sun H, Li Q, Liu Y, Xie J, Feng Y, Shang Y, Ma K, Zhang N, Wang J (2023) Construction and validation of a nomogram to predict the overall survival of small cell lung cancer: a multicenter retrospective study in Shandong province, China. BMC Cancer 23(1):1182","journal-title":"BMC Cancer"},{"key":"3803_CR42","doi-asserted-by":"publisher","first-page":"1148425","DOI":"10.3389\/fimmu.2023.1148425","volume":"14","author":"HY Gu","year":"2023","unstructured":"Gu HY, Zhao JW, Wang YS, Meng ZN, Zhu XM, Wang FW, Zheng AH, Wu GQ (2023) Case report: life-threatening pancytopenia with tislelizumab followed by cerebral infarction in a patient with lung adenocarcinoma. Front Immunol 14:1148425","journal-title":"Front Immunol"},{"issue":"1","key":"3803_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00277-021-04690-x","volume":"101","author":"P Ghanem","year":"2022","unstructured":"Ghanem P, Marrone K, Shanbhag S, Brahmer JR, Naik RP (2022) Current challenges of hematologic complications due to immune checkpoint blockade: a comprehensive review. Ann Hematol 101(1):1\u201310","journal-title":"Ann Hematol"},{"key":"3803_CR44","doi-asserted-by":"publisher","first-page":"790051","DOI":"10.3389\/fimmu.2021.790051","volume":"12","author":"W Xie","year":"2021","unstructured":"Xie W, Hu N, Cao L (2021) Immune thrombocytopenia induced by immune checkpoint inhibitrs in lung cancer: case report and literature review. Front Immunol 12:790051","journal-title":"Front Immunol"},{"key":"3803_CR45","doi-asserted-by":"publisher","first-page":"840313","DOI":"10.3389\/fimmu.2022.840313","volume":"13","author":"H Wang","year":"2022","unstructured":"Wang H, Zhou F, Zhao C, Cheng L, Zhou C, Qiao M, Li X, Chen X (2022) Interleukin-10 is a promising marker for immune-related adverse events in patients with non-small cell lung cancer receiving immunotherapy. Front Immunol 13:840313","journal-title":"Front Immunol"},{"issue":"3","key":"3803_CR46","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/1759-7714.13281","volume":"11","author":"J Zhuang","year":"2020","unstructured":"Zhuang J, Du J, Guo X, Zhou J, Duan L, Qiu W, Si X, Zhang L, Li Y, Liu X, Wang H, Zhou D, Zhang L (2020) Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events. Thorac Cancer 11(3):799\u2013804","journal-title":"Thorac Cancer"},{"issue":"11","key":"3803_CR47","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/jhm.13097","volume":"18","author":"SD Chitnis","year":"2023","unstructured":"Chitnis SD, Mortazavi A (2023) Clinical guideline highlights for the hospitalist: management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy. J Hosp Med 18(11):1013\u20131016","journal-title":"J Hosp Med"},{"key":"3803_CR48","doi-asserted-by":"crossref","unstructured":"Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, Lyon AR, Wick W, Kostine M, Peters S, Jordan K, Larkin J, clinicalguidelines@esmo.org EGCEa (2022) Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 33(12):1217\u20131238","DOI":"10.1016\/j.annonc.2022.10.001"},{"issue":"4","key":"3803_CR49","doi-asserted-by":"publisher","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","volume":"20","author":"JA Thompson","year":"2022","unstructured":"Thompson JA, Schneider BJ, Brahmer J, Achufusi A, Armand P, Berkenstock MK, Bhatia S, Budde LE, Chokshi S, Davies M, Elshoury A, Gesthalter Y, Hegde A, Jain M, Kaffenberger BH, Lechner MG, Li T, Marr A, McGettigan S, McPherson J, Medina T, Mohindra NA, Olszanski AJ, Oluwole O, Patel SP, Patil P, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wang Y, Zaha VG, Lyons M, Dwyer M, Hang L (2022) Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 20(4):387\u2013405","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"3803_CR50","doi-asserted-by":"publisher","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","volume":"9","author":"JR Brahmer","year":"2021","unstructured":"Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, Gerber DE, Hamad L, Hansen E, Johnson DB, Lacouture ME, Masters GA, Naidoo J, Nanni M, Perales MA, Puzanov I, Santomasso BD, Shanbhag SP, Sharma R, Skondra D, Sosman JA, Turner M, Ernstoff MS (2021) Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 9(6):e002435","journal-title":"J Immunother Cancer"},{"key":"3803_CR51","doi-asserted-by":"publisher","first-page":"1163971","DOI":"10.3389\/fphar.2023.1163971","volume":"14","author":"J Hou","year":"2023","unstructured":"Hou J, Xie R, Zhang Z, Liu Q, Xiang Q, Cui Y (2023) Hematologic side effects of immune checkpoint inhibitor with or without chemotherapy in patients with advanced and metastatic gastrointestinal cancer: a systematic review and network meta-analysis of phase 3 trials. Front Pharmacol 14:1163971","journal-title":"Front Pharmacol"},{"issue":"11","key":"3803_CR52","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.21037\/tlcr-22-745","volume":"11","author":"G Qiu","year":"2022","unstructured":"Qiu G, Li S, Li B, Yang Q, Deng H, Yang Y, Xie X, Lin X, Seki N, Miura S, Shukuya T, Zhou C, Liu M (2022) Immune thrombocytopenia in a small cell lung cancer patient treated with atezolizumab: a case report. Transl Lung Cancer Res 11(11):2346\u20132355","journal-title":"Transl Lung Cancer Res"},{"issue":"9","key":"3803_CR53","first-page":"e45675","volume":"15","author":"A Waqas","year":"2023","unstructured":"Waqas A, Zaffar J, Jalil A, Butt S (2023) Nivolumab-induced isolated neutropenia. Cureus 15(9):e45675","journal-title":"Cureus"},{"issue":"9","key":"3803_CR54","first-page":"717","volume":"26","author":"J Cai","year":"2023","unstructured":"Cai J, Yang G, Zhang X, Liu L, Yan M (2023) Immune thrombocytopenia induced by sintilimab in lung cancer: a case report and literature review. Zhongguo Fei Ai Za Zhi 26(9):717\u2013720","journal-title":"Zhongguo Fei Ai Za Zhi"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03803-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03803-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03803-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T07:45:10Z","timestamp":1742370310000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03803-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3803"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03803-z","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]},"assertion":[{"value":"2 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}